These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8114270)

  • 21. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1998)].
    Ikemoto H; Arakawa M; Gejyo F; Igarashi K; Mori T; Okada M; Ozaki K; Igari J; Aoki N; Oguri T; Kitamura N; Terai T; Sekine O; Suzuki Y; Inoue H; Nakadate T; Karasawa Y; Ito C; Yoshida T; Nakata K; Nakatani T; Ohno I; Okada S; Inagawa H; Kudo K; Kobayashi N; Ando M; Suga M; Sato K; Kondo T; Tosaka M; Kobayashi H; Kawai S; Takayasu S; Kohno S; Tomono K; Shimada K; Nakano K; Miyazaki Y; Izumikawa K; Yamaguchi T; Mochida C; Yokouchi H; Ito A; Sumitomo M; Nasu M; Nagai H; Yamasaki T; Matsushima T; Nakano T
    Jpn J Antibiot; 2000 May; 53(5):261-98. PubMed ID: 10923284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1999)].
    Shimada K; Nakano K; Ohno I; Okada S; Hayashi K; Yokouchi H; Arakawa M; Gejyo F; Igarashi K; Ikemoto H; Mori T; Okada M; Ozaki K; Igari J; Aoki N; Oguri T; Kitamura N; Terai T; Suzuki Y; Inoue H; Nakadate T; Karasawa Y; Ito C; Yoshida T; Nakata K; Nakatani T; Inagawa H; Ando M; Suga M; Sato K; Kudo K; Kobayashi N; Tosaka M; Hasegawa M; Kohno S; Tomono K; Miyazaki Y; Kobayashi H; Kawai S; Takayasu S; Hirakata Y; Matsuda J; Mochida C; Ito A; Sumitomo M; Nasu M; Nagai H; Matsushima T; Niki Y; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2001 Jul; 54(7):331-64. PubMed ID: 11560054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2002)].
    Shimada K; Nakano K; Igari J; Oguri T; Ikemoto H; Mori T; Yokouchi H; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Okada S; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Nakata K; Nakatani T; Inagawa H; Kudo K; Kobayashi N; Tanaka T; Kobayashi H; Goto H; Kawai S; Takeda H; Sumitomo M; Matsushima T; Niki Y; Kohno S; Miyazaki Y; Yanagihara K; Hirakata Y; Matsuda J; Nasu M; Hiramatsu K; Suga M; Tosaka M
    Jpn J Antibiot; 2004 Jun; 57(3):213-45. PubMed ID: 15376784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
    Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
    Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
    Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
    Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2009)].
    Goto H; Kumagai S
    Jpn J Antibiot; 2015 Feb; 68(1):37-54. PubMed ID: 25980052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
    Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
    Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
    Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antibacterial activity of tosufloxacin against fresh clinical isolates].
    Yamashiro Y; Shimakura M; Minami S; Fukuoka Y; Yasuda T; Watanabe Y; Narita H; Akama M
    Jpn J Antibiot; 1994 Mar; 47(3):245-54. PubMed ID: 8182895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2007)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Feb; 68(1):1-18. PubMed ID: 25980050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2004)].
    Goto H; Takeda H; Kawai S; Watanabe T; Okazaki M; Shimada K; Nakano K; Yokouchi H; Ikemoto H; Mori T; Igari J; Oguri T; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Kudo K; Kobayashi N; Tanaka T; Sumitomo M; Matsushima T; Oka M; Niki Y; Suga M; Tosaka M; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Nasu M; Hiramatsu K; Oikawa S
    Jpn J Antibiot; 2006 Oct; 59(5):323-54. PubMed ID: 17180803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan.
    Tsurumaki Y; Manda H; Takei M; Hosaka M
    J Antimicrob Chemother; 2000 May; 45(5):685-9. PubMed ID: 10797094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
    Pucci MJ; Cheng J; Podos SD; Thoma CL; Thanassi JA; Buechter DD; Mushtaq G; Vigliotti GA; Bradbury BJ; Deshpande M
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1259-67. PubMed ID: 17242152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2006)].
    Goto H; Takeda H; Kawai S; Suwabe A; Watanabe S; Okazaki M; Ashino Y; Shimada K; Aoki N; Sato T; Honma Y; Mori T; Kudo K; Sugiyama H; Kondo S; Tanaka T; Kido K; Yoshimura K; Oguri T; Yamamoto M; Nakamori Y; Inoue H; Yamauchi K; Sumitomo M; Endo S; Nakadate T; Oka M; Kobashi Y; Saita N; Yanagihara K; Kondou A; Matsuda J; Nakano M; Kohno S; Oikawa S
    Jpn J Antibiot; 2013 Dec; 66(6):331-55. PubMed ID: 24649798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antibacterial activities of new quinolones against fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1994 Oct; 47(10):1379-400. PubMed ID: 7807698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.